药物开发商Viking Therapeutics(VKTX.US)盘前涨16.3%，报33.2美元。消息面上，Viking Therapeutics计划于今年第三季度将其试验性减肥药VK2735的片剂推进到后期研究阶段。公司称，中期研究数据显示，通过低剂量口服治疗策略可以有效维持体重。奥本海默分析师称，VK2735的监管途径与其注射减肥药项目相比具有优势，可能缩短试验时间并缩小试验规模。(格隆汇)
药物开发商Viking Therapeutics(VKTX.US)盘前涨16.3%，报33.2美元。消息面上，Viking Therapeutics计划于今年第三季度将其试验性减肥药VK2735的片剂推进到后期研究阶段。公司称，中期研究数据显示，通过低剂量口服治疗策略可以有效维持体重。奥本海默分析师称，VK2735的监管途径与其注射减肥药项目相比具有优势，可能缩短试验时间并缩小试验规模。(格隆汇)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.